secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verrica Pharmaceuticals Inc. (VRCA)
CIK:        0001660334
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001193125-24-136715
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verrica Q1 2024: YCANTH revenue $3.2M, net loss $20.3M, cash runway into Q1 2025
--------------------------------------------------------------------------------

- YCANTH product revenue of $3.2M; no prior-year comparable as sales began Q3 2023.
- Net loss $20.3M ($0.44/sh) vs $6.6M loss ($0.15/sh) in Q1 2023; non-GAAP loss $17.8M.
- SG&A expense surged to $16.3M from $4.3M due to commercial ramp; R&D $4.9M vs $2.7M.
- Cash and equivalents $48.9M; company expects to fund operations into Q1 2025.
- Received NCE status (5-year exclusivity) and permanent J-Code for YCANTH; Phase 2 data for VP-315 (BCC) expected Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1660334/000119312524136715/0001193125-24-136715-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1660334/000119312524136715/d805970d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-136715

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer